Table 1

Lung injury following ischemia and reperfusion

Group

% injured alveoli

MPO activity^a

Wet/dry weight ratio

i

2.8 ± 1.3*

1.4 ± 0.3*

4.8 ± 0.4

ii

35.0 ± 2.2

4.7 ± 0.3

8.6 ± 0.3

IB-MECA groups

iii (50 μg/kg)

32.5 ± 2.3**

4.4 ± 0.3**

8.0 ± 0.3**

iv (100 μg/kg)

27.7 ± 1.4^# **

3.6 ± 0.2^# **

6.4 ± 0.3^# **

v (300 μg/kg)

21.0 ± 1.5^#

2.3 ± 0.2^#

5.2 ± 0.2^#

MRS3558 groups

vi (50 μg/kg)

22.2 ± 1.5^#

2.4 ± 0.3^#

5.3 ± 0.4^#

vii (100 μg/kg)

20.1 ± 2.2^#

2.0 ± 0.2^#

4.9 ± 0.3^#

viii (MRS3558-MRS1191 group)

37.7 ± 1.5

4.8 ± 0.3

8.5 ± 0.3

Values are expressed as means ± standard error of the mean (n = 5–6 cats/group). IB-MECA and MRS3558 are A₃ adenosine receptor (AR) agonists, and MRS1191 is an A₃AR antagonist. The groups were as follows: i = nonischemic group; ii = ischemia/reperfusion; iii, iv and v = IB-MECA 50 μg/kg, 100 μg/kg and 300 μg/kg, respectively, administered 1 hour before reperfusion; vi and vii = MRS3558 50 μg/kg and 100 μg/kg, respectively, administered before reperfusion; and viii = MRS1191 pretreatment before MRS3558 (100 μg/kg) and beginning of reperfusion. ^aTissue myeloperoxidase (MPO) activity is expressed in units of MPO/g of lung weight, each of which was defined as the activity degrading 1 μmol of peroxide per minute at 25°C. *P < 0.01 versus the other groups; **P < 0.05 versus MRS3558 groups and IB-MECA 300 μg/kg group; ^#P < 0.05 versus IR and MRS3558-MRS1191 groups (see text for further comparisons).

Matot et al. Critical Care 2006 10:R65   doi:10.1186/cc4893